Healthcare
Live Price
Offline$19.00
-0.21% today
1Y Change
+113.17%
Window
Jun 23, 2025 → May 29, 2026
Coverage: 236 bars · Jun 23, 2025 → May 29, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Syndax Pharmaceuticals, Inc. (SNDX) is a Healthcare stock with a market cap of $1.69B and listed on NASDAQ. The stock last traded around $19.00 and up 113.2% across the available one-year price window (Jun 23, 2025 → May 29, 2026). Baseline metrics include revenue growth of +627.8%, EPS growth of +11.8%, a dividend yield of 0.0%. What stands out right now is revenue +627.8%, EPS +11.8%, free cash flow -17.6% with operating margin -102.9% and ROIC -57.8%. Valuation sits in the middle of the pack at price/sales 7.8. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines SNDX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SNDX
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SNDX Max Drawdown
-24.02%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SNDX and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$139.7M
FY Net Income
$24.9M
+116.7% YoY
Free Cash Flow
$29.0M
+121.7% YoY
Revenue Growth
+627.8%
EPS Growth
+11.8%
Gross Margin
98.0%
Net Margin
-112.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 172M | 24M | 0 | 0 | 140M |
| Gross Profit | 165M | 23M | 0 | 0 | 140M |
| Operating Income | -273M | -340M | -230M | -152M | 26M |
| EBITDA | -252M | -314M | -209M | -146M | 27M |
| Net Income | -285M | -319M | -209M | -149M | 25M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 135M | 154M | 295M | 74M | 222M |
| Total Assets | 530M | 725M | 613M | 497M | 450M |
| Total Liabilities | 465M | 437M | 59M | 30M | 41M |
| Shareholder Equity | 65M | 288M | 554M | 467M | 408M |
| Total Debt | 346M | 346M | 2M | 1M | 21M |
| Net Debt | 212M | 192M | -294M | -73M | -201M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
29M
+121.8% YoY
Capital Expenditures
129K
+42.7% YoY
Free Cash Flow
29M
+121.7% YoY
Key ratios
Gross Margin
98.0%
Operating Margin
-102.9%
Net Margin
-112.0%
ROE
-256.7%
Debt / Equity
8.30x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.